Core Insights - Check Point Software (CHKP) has a strong track record of exceeding earnings estimates, particularly in the last two quarters, with an average surprise of 30.62% [1] - In the last reported quarter, Check Point achieved earnings of $3.94 per share, significantly surpassing the Zacks Consensus Estimate of $2.45 per share by 60.82% [2] - The previous quarter also saw Check Point slightly exceed expectations, reporting earnings of $2.37 per share against an estimate of $2.36 per share, resulting in a surprise of 0.42% [2] Earnings Estimates and Predictions - There has been a favorable shift in earnings estimates for Check Point, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have historically produced positive surprises nearly 70% of the time, suggesting a high probability of exceeding consensus estimates [6] - Check Point currently has an Earnings ESP of +0.08%, reflecting recent bullish sentiment among analysts regarding the company's earnings prospects [8] Upcoming Earnings Report - The next earnings report for Check Point is anticipated to be released on February 12, 2026, and the combination of a positive Earnings ESP and a Zacks Rank 3 suggests a potential for another earnings beat [8]

Core Insights - Hagerty, Inc. (HGTY) has a strong track record of beating earnings estimates, with an average surprise of 31.31% over the last two quarters [1][2] Earnings Performance - For the last reported quarter, Hagerty achieved earnings of $0.13 per share, exceeding the Zacks Consensus Estimate of $0.09 per share, resulting in a surprise of 44.44% [2] - In the previous quarter, the company was expected to report earnings of $0.11 per share but delivered $0.13 per share, leading to a surprise of 18.18% [2] Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Hagerty, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5] - The current Earnings ESP for Hagerty is +14.29%, suggesting that analysts are optimistic about the company's earnings prospects [8] - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) indicates a high probability of another earnings beat [8] Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7]

Investors interested in Electronics - Semiconductors stocks are likely familiar with Infineon Technologies AG (IFNNY) and Lattice Semiconductor (LSCC) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with str ...

Core Viewpoint - Investors in the Diversified Operations sector should consider Grupo Cibest (CIB) and ITT (ITT) for potential value investment opportunities, with CIB appearing more attractive based on various valuation metrics [1]. Valuation Metrics - Grupo Cibest (CIB) has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while ITT has a Zacks Rank of 3 (Hold) [3]. - CIB's forward P/E ratio is 9.92, significantly lower than ITT's forward P/E of 24.41, suggesting that CIB may be undervalued [5]. - CIB has a PEG ratio of 0.99, compared to ITT's PEG ratio of 1.64, indicating that CIB's valuation is more favorable when considering expected earnings growth [5]. - CIB's P/B ratio is 2.25, while ITT's P/B ratio is 5.32, further supporting the notion that CIB is a better value option [6]. - CIB's overall Value grade is B, whereas ITT's Value grade is D, highlighting the relative attractiveness of CIB as a value investment [6]. Earnings Outlook - CIB is noted for its improving earnings outlook, which enhances its appeal in the Zacks Rank model, suggesting it is a superior value option at this time [7].

Core Viewpoint - T. Rowe Price Group, Inc. (TROW) is expected to report an increase in both earnings and revenues for the fourth quarter of 2025 compared to the previous year, despite facing challenges such as net outflows and rising expenses [1][7]. Financial Performance - In the last reported quarter, TROW's earnings exceeded the Zacks Consensus Estimate, driven by higher assets under management (AUM) and increased investment advisory fees, although higher expenses negatively impacted results [2][6]. - The consensus estimate for fourth-quarter earnings is $2.46 per share, reflecting a year-over-year increase of 16%, while revenues are estimated at $1.92 billion, indicating a 5.1% rise from the prior year [8][9]. Assets Under Management - TROW's preliminary AUM as of December 31, 2025, is $1.78 trillion, showing a slight increase from September 30, 2025, supported by improved performance in fixed income, multi-asset, and alternative products [4][5]. - The Zacks Consensus Estimate for total AUM is also pegged at $1.78 trillion, indicating a marginal sequential increase [5]. Market Conditions - The S&P 500 Index gained approximately 3.1% during the October-December quarter, suggesting moderate market performance, which likely benefited TROW through steady fixed-income inflows and stable equity market returns [3]. Net Outflows and Expenses - TROW experienced net outflows of $11.6 billion for the quarter ended December 31, 2025, amid a challenging operating environment [4]. - The company continues to incur significant expenses to attract new clients and invest in technology and employee compensation, which is expected to have increased overall expenses for the quarter [6].

Core Insights - Lightspeed Commerce (LSPD) is set to announce its third-quarter fiscal 2026 results on February 5, with earnings estimated at 12 cents per share and revenues projected at $311.63 million, reflecting an 11.25% year-over-year increase [1][8] Group 1: Performance Expectations - The fiscal third-quarter performance is expected to benefit from positive operating trends and strategic transformation efforts, including an expanded outbound sales organization and improved software average revenue per user [3][8] - Transaction-based revenue growth is anticipated due to sustained payments penetration, especially in international markets, and the introduction of the Tempo solution for restaurant operators is expected to enhance operational efficiency in European hospitality [4][8] Group 2: Challenges Ahead - Seasonal weakness in European hospitality and golf operations during winter months is expected to negatively impact performance, with reduced customer traffic affecting gross transaction value and same-store sales [5] - Software revenue growth may moderate as the company cycles through previous price increases, and shifts in geographic and vertical mix could pressure overall growth rates compared to the strong fiscal second quarter [5] Group 3: Earnings Model Insights - According to the Zacks model, the current Earnings ESP for Lightspeed is 0.00% with a Zacks Rank of 3, indicating that the odds of an earnings beat are not favorable at this time [6]

Key Takeaways NWSA to report Q2 results on Feb. 5, with consensus revenues of $2.31B, implying a 3.21% year-over-year gain.NWSA's EPS estimate is 33 cents, unchanged year over year, pointing to limited bottom-line expansion.NWSA's Book Publishing was expected to rebound, while digital revenues at 62% of sales offset softness.News Corporation (NWSA) is scheduled to report second-quarter fiscal 2026 results on Feb. 5.The Zacks Consensus Estimate for revenues is pegged at $2.31 billion, indicating growth of 3. ...

Key Takeaways AMCR will report Q2 FY26 results on Feb. 3, with revenues seen at $5.55B and earnings of 83 cents per share.AMCR's outlook reflects a major revenue boost from the Berry Global merger, offsetting volume pressure.AMCR's segments face volume declines, cushioned by price/mix gains, currency benefits and acquisitions.Amcor Plc (AMCR) is scheduled to report second-quarter fiscal 2026 results on Feb. 3, after the closing bell.The Zacks Consensus Estimate for AMCR’s fiscal second-quarter revenues is p ...

Core Viewpoint - AbbVie is expected to report fourth-quarter and full-year 2025 earnings on February 4, with sales projected at $16.36 billion and earnings per share (EPS) at $2.66, although EPS estimates for 2025 and 2026 have declined recently [2][6]. Earnings Performance - AbbVie has consistently exceeded earnings expectations in the past four quarters, with an average earnings surprise of 3.05%, including a 5.08% surprise in the last quarter [4][6]. Revenue Drivers - The anticipated revenue growth for AbbVie in Q4 2025 is primarily driven by increased sales of newer immunology drugs, Skyrizi and Rinvoq, as sales of the flagship drug Humira continue to decline due to biosimilar competition [9][10]. - The Zacks Consensus Estimate for Skyrizi sales is $4.91 billion, while Rinvoq is estimated at $2.39 billion [9]. Sales Estimates - Humira's sales are projected at $949 million, reflecting ongoing erosion from biosimilars, while Imbruvica sales are expected to decline to $715 million due to competition [10]. - Sales for Roche-partnered Venclexta are estimated to rise to $725 million, driven by strong demand [11]. - Neuroscience product sales are expected to reach approximately $3.00 billion, supported by strong performances from Botox Therapeutic, Vraylar, and new migraine drugs [12]. - Aesthetics product sales are projected at $1.28 billion, showing signs of recovery from previous sluggishness [13]. Valuation and Market Position - AbbVie shares are currently trading at a P/E ratio of 15.38, below the industry average of 18.42, indicating a discount relative to peers [17]. - Despite underperforming the industry over the past year, AbbVie is expected to achieve robust revenue growth driven by its newer drug launches [19]. Future Outlook - AbbVie anticipates a high single-digit revenue compound annual growth rate (CAGR) through 2029, supported by the successful launches of Skyrizi and Rinvoq [19]. - The company continues to invest in its pipeline through strategic collaborations, including a recent licensing deal with RemeGen for a bispecific antibody candidate [21]. - A favorable valuation and strong earnings growth expectations provide a compelling case for long-term investment in AbbVie stock [22].

Core Insights - Symbotic Inc. (SYM) is expected to report first-quarter fiscal 2026 results on February 4, with revenue estimates at $622.31 million, reflecting a 27.9% year-over-year growth and earnings estimated at 8 cents per share, indicating a 366.7% increase from the previous year [1][7]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for SYM's revenues in Q1 is $622.31 million, with a projected growth rate of 25-29% based on backlog conversion [1][5]. - The earnings estimate for Q1 remains stable at 8 cents per share over the past 60 days, with no revisions [2][3]. Backlog and Growth Drivers - SYM reported a backlog of $22.5 billion in Q4 of fiscal 2025, which is anticipated to drive revenue growth in Q1 fiscal 2026 [5]. - The company projects adjusted EBITDA between $49 million and $53 million for the first quarter [5]. Cost and Margin Concerns - High operating costs, particularly in research and development and selling, general, and administrative expenses, are expected to negatively impact bottom-line performance [6][15]. - The company's significant investments to maintain technological advantages have contributed to increased costs [6]. Stock Performance and Valuation - SYM's shares have declined over 33% in the past three months, underperforming its industry and peers [7][8]. - The company is considered relatively overvalued, trading at a high forward 12-month price-to-sales ratio compared to industry averages and competitors [11]. Customer Dependency - SYM's reliance on Walmart, its largest customer, raises concerns, as this partnership constitutes a significant portion of its revenues [15]. - The acquisition of Walmart's advanced systems and robotics business in January 2025 has further solidified this dependency [15].